Medtronic PLC $MDT Shares Acquired by Associated Banc Corp

Associated Banc Corp raised its position in shares of Medtronic PLC (NYSE:MDT) by 3.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 184,793 shares of the medical technology company’s stock after buying an additional 5,661 shares during the quarter. Associated Banc Corp’s holdings in Medtronic were worth $17,600,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in MDT. Brighton Jones LLC boosted its holdings in Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after purchasing an additional 37,265 shares during the period. Jones Financial Companies Lllp lifted its position in shares of Medtronic by 32.2% in the 1st quarter. Jones Financial Companies Lllp now owns 690,119 shares of the medical technology company’s stock worth $60,777,000 after buying an additional 168,092 shares during the last quarter. Modern Wealth Management LLC boosted its holdings in shares of Medtronic by 25.5% in the 1st quarter. Modern Wealth Management LLC now owns 17,478 shares of the medical technology company’s stock valued at $1,571,000 after buying an additional 3,550 shares during the period. Hodges Capital Management Inc. grew its position in shares of Medtronic by 49.7% during the 1st quarter. Hodges Capital Management Inc. now owns 8,663 shares of the medical technology company’s stock valued at $778,000 after buying an additional 2,876 shares during the last quarter. Finally, First Hawaiian Bank raised its stake in Medtronic by 12.1% during the first quarter. First Hawaiian Bank now owns 25,092 shares of the medical technology company’s stock worth $2,255,000 after acquiring an additional 2,699 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Down 1.2%

MDT opened at $97.54 on Friday. The stock’s 50 day moving average price is $98.31 and its 200 day moving average price is $94.51. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The stock has a market cap of $125.04 billion, a P/E ratio of 26.29, a P/E/G ratio of 2.57 and a beta of 0.71. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the prior year, the business posted $1.26 earnings per share. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be paid a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is presently 76.55%.

Analyst Ratings Changes

A number of brokerages have issued reports on MDT. The Goldman Sachs Group set a $111.00 target price on shares of Medtronic and gave the stock a “neutral” rating in a report on Wednesday, November 19th. JPMorgan Chase & Co. raised their price target on Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a report on Thursday, November 13th. Citigroup boosted their price objective on Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research report on Tuesday, October 7th. Sanford C. Bernstein upped their price objective on Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $110.00 target price on shares of Medtronic in a research note on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eleven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $110.28.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).